SameemMAbedinMD

Hematologic Oncology

Associate Professor

Dr. Abedin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Sameem Abedin, MD, is an oncologist with a subspecialty in Hematologic Oncology, located in Milwaukee, WI. He completed his fellowship at the McGaw Medical Center of Northwestern University and has previously worked as a Fellow at Northwestern Memorial Hospital and as an Attending Physician at the University of Michigan Medical Center. His familiarity spans across hematologic oncology, bone marrow transplantation, and leukemia. He has several publications to his name and has contributed to clinical trials related to Acute Myeloid Leukemia, Acute Graft Versus Host Disease, and high-risk myelodysplastic syndrome.

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2014 - 2017
UPMC Medical EducationResidency, Internal Medicine, 2009 - 2012
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2009

PubMed

Abstracts/Posters

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Sy...
Sameem Abedin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)
Sameem Abedin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparaginase Based Regimens
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

$Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-a CLAG-M Combination Trial Oral Presentation at ASH$
Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-a CLAG-M Combination Trial Oral Presentation at ASHDecember 12th, 2022
$Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-a CLAG-M Combination Trial$
Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-a CLAG-M Combination TrialNovember 3rd, 2022
$Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-a in Combination with CLAG-M for Patients with Relapsed or Refractory AML$
Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-a in Combination with CLAG-M for Patients with Relapsed or Refractory AMLDecember 14th, 2021
Join now to see all